Table 1.
Patient and Transplant characteristics.
| Full matches |
TCE Permissive mismatches |
TCE Non-permissive mismatches |
P-valuea | |
|---|---|---|---|---|
| Variable | N (%) | N (%) | N (%) | |
| Number of Patients | 239 | 585 | 457 | |
| Number of Centers | 54 | 84 | 82 | |
| Median Recipient Age | 36 (1–61) | 36 (<1–65) | 36 (<1–63) | 0.31 |
| Recipient Age | 0.57 | |||
| 0–9 | 17 (7) | 46 (8) | 36 (8) | |
| 10–19 | 17 (7) | 62 (11) | 45 (10) | |
| 20–29 | 39 (16) | 106 (18) | 78 (17) | |
| 30–39 | 61 (26) | 135 (23) | 117 (26) | |
| 40–49 | 62 (26) | 152 (26) | 128 (28) | |
| 50+ | 43 (18) | 84 (14) | 53 (12) | |
| Recipient Race/Ethnicity | 0.25 | |||
| Caucasian | 217 (91) | 551 (94) | 431 (94) | |
| African American | 3 (1) | 9 (2) | 6 (1) | |
| Asian/Pac. Islander | 4 (2) | 5 (1) | 2 (<1) | |
| Hispanic | 12 (5) | 19 (3) | 14 (3) | |
| Native American | 0 | 1 (<1) | 0 | |
| Other/Multiple/Unknown | 3 (1) | 0 | 4 (1) | |
| Sex | 0.79 | |||
| Male | 136 (57) | 331 (57) | 268 (59) | |
| Female | 103 (43) | 254 (43) | 189 (41) | |
| Karnofsky Score | 0.58 | |||
| < 90 | 67 (28) | 134 (23) | 119 (26) | |
| >= 90 | 162 (68) | 426 (73) | 320 (70) | |
| Missing | 10 (4) | 25 (4) | 18 (4) | |
| Disease | 0.03 | |||
| AML | 66 (28) | 153 (26) | 133 (29) | |
| ALL | 39 (16) | 137 (23) | 105 (23) | |
| CML | 102 (43) | 188 (32) | 153 (33) | |
| MDS | 32 (13) | 107 (18) | 66 (14) | |
| Disease Status at Txb | 0.09 | |||
| Early | 167 (70) | 407 (70) | 319 (70) | |
| Intermediate | 11 (5) | 34 (6) | 22 (5) | |
| Advanced | 61 (26) | 132 (23) | 114 (25) | |
| Other | 0 | 12 (2) | 2 (<1) | |
| HLA-DPB1 Matching | < 0.0001 | |||
| Two Mismatches | 0 | 126 (22) | 234 (51) | |
| One Mismatch | 0 | 459 (78) | 223 (49) | |
| Fully Matched | 239 (100) | 0 | 0 | |
| HLA-DPA1*0201 | < 0.0001 | |||
| Absent | 181 (76) | 295 (50) | 183 (40) | |
| Present | 58 (24) | 290 (50) | 274 (60) | |
| HLA-DPA1 allele | < 0.0001 | |||
| Matched | 229 (96) | 321 (55) | 219 (48) | |
| Mismatched | 10 (4) | 264 (45) | 238 (52) | |
| Graft Type | 0.08 | |||
| Bone Marrow | 206 (86) | 513 (88) | 417 (91) | |
| PBSC | 33 (14) | 72 (12) | 40 (9) | |
| GVHD Prophylaxis | 0.004 | |||
| FK506 + (MTX, MMF or Steroids) ± Other | 70 (29) | 147 (25) | 132 (29) | |
| FK506 ± Other | 2 (1) | 2 (<1) | 1 (<1) | |
| CSA + MTX ± Other | 155 (65) | 416 (71) | 294 (64) | |
| CSA ± Other (No MTX) | 8 (3) | 17 (3) | 25 (5) | |
| MTX ± Other (No CSA) | 0 | 1 (<1) | 5 (1) | |
| Other | 4 (2) | 2 (<1) | 0 | |
| In vivo T-cell depletion | 0.49 | |||
| Yes | 31 (13) | 60 (10) | 54 (12) | |
| No | 208 (87) | 525 (90) | 403 (88) | |
| Sex Match | 0.11 | |||
| Male -> Male | 88 (37) | 233 (40) | 200 (44) | |
| Male -> Female | 60 (25) | 127 (22) | 115 (25) | |
| Female -> Male | 48 (20) | 98 (17) | 68 (15) | |
| Female -> Female | 43 (18) | 127 (22) | 74 (16) | |
| CMV Match | 0.92 | |||
| Negative/Negative | 81 (34) | 208 (36) | 167 (37) | |
| Negative/Positive | 64 (27) | 159 (27) | 128 (28) | |
| Positive/Negative | 40 (17) | 98 (17) | 65 (14) | |
| Positive/Positive | 48 (20) | 103 (18) | 88 (19) | |
| Unknown | 6 (3) | 17 (3) | 9 (2) | |
| Median Donor Age | 35 (18–59) | 36 (18–60) | 35 (19–57) | 0.10 |
| Donor Age | 0.45 | |||
| 18–29 | 69 (29) | 154 (26) | 133 (29) | |
| 30–39 | 88 (37) | 228 (39) | 192 (42) | |
| 40–49 | 64 (27) | 167 (29) | 105 (23) | |
| 50+ | 18 (8) | 36 (6) | 27 (6) | |
| Conditioning Regimen | 0.87 | |||
| Cy + TBI | 181 (76) | 421 (72) | 329 (72) | |
| Bu + Cy | 39 (16) | 124 (21) | 96 (21) | |
| TBI 500 single dose or 800 fractionated | 10 (4) | 22 (4) | 19 (4) | |
| Melphalan > 150 mg/m2 | 5 (2) | 9 (2) | 5 (1) | |
| Bu > 9 mg/kg | 4 (2) | 9 (2) | 8 (2) | |
| Year of Transplant | 0.61 | |||
| 1988–1991 | 8 (3) | 23 (4) | 15 (3) | |
| 1992–1994 | 41 (17) | 72 (12) | 63 (14) | |
| 1995–1997 | 49 (21) | 146 (25) | 116 (25) | |
| 1998–2000 | 85 (36) | 189 (32) | 151 (33) | |
| 2001–2003 | 56 (23) | 155 (26) | 112 (25) | |
| Median follow-up of survivors, months | 99 (13 – 200) | 106 (10 – 245) | 102 (22 – 196) | 0.52b |
Abbreviations:
CsA = Cyclosporine; CMV = Cytomegalovirus; FK506 = Tacrolimus; HLA = Human leukocyte antigens; MMF = Mycophenolate mofetil; MTX = Methotrexate; tx = transplant.
a
Log-rank p-value.
b
Early stage disease was defined as AML or ALL in first complete remission, CML in first chronic phase, and MDS subtype refractory anemia. Intermediate stage disease was defined as AML or ALL in second or subsequent complete remission, and CML in accelerated phase or second chronic phase. Advanced phase disease was defined as AML in first or higher relapse or primary induction failure, CML in blast phase, MDS subtypes refractory anemia with excess blasts or in transformation.